Therapies in development for castrate-resistant prostate cancer

References

• Mohler JL, Gregory CW, Ford OH et al. The androgen axis in recurrent prostate cancer. Clin. Cancer Res.10(2), 440–448 (2004).
   PubMed Web of Science ®Google Scholar
• Attard G, Yap TA, Reid AH et al. Phase I study of continuous oral dosing of an irreversible CYP17 inhibitor, abiraterone in castration refractory prostate cancer patients incorporating the evaluation of androgens and steroid metabolites in plasma and tumor. J. Clin. Oncol.25(Suppl. 18), 5063 (2007).
   PubMedGoogle Scholar
• Ryan CJ, Rosenberg J, Lin A et al. Phase I Evaluation of abiraterone acetate (CB7630), a 17 alpha hydroxylase C17,20-Lyase inhibitor in androgen-independent prostate cancer (AiPC). J. Clin. Oncol.25(Suppl. 18), 5064 (2007).
   Google Scholar
• Lin AM, Rini BI, Weinberg V et al. A Phase II trial of imatinib mesylate in patients with a biochemical relapse of prostate cancer after definitive local therapy. BJU Int.98(4), 763–769 (2006).
   PubMed Web of Science ®Google Scholar
• Collette L. Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trials. Eur. Urol. (Epub ahead of print). (2007).
   Google Scholar
• George DJ, Halabi S, Shepard TF et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on cancer and leukemia group B 9480. Clin. Cancer Res.7(7), 1932–1936 (2001).
   PubMed Web of Science ®Google Scholar
• Bok RA, Halabi S, Fei DT et al. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res.61(6), 2533–2536 (2001).
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.350(23), 2335–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC et al. Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med.355(24), 2542–2550 (2006).
   PubMed Web of Science ®Google Scholar
• Miller KD, Chap LI, Holmes FA et al. Randomized Phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol.23(4), 792–799 (2005).
   PubMed Web of Science ®Google Scholar
• Reese DM, Fratesi P, Corry M et al. A Phase II trial of humanized anti-vascular endothelial growth factor antibody for the treatment of androgen-independent prostate cancer. Prostate J.3(2), 65–70 (2001).
   Google Scholar
• Picus J, Halabi S, Rini B et al. The use of bevacizumab with docetaxel and estramustine in hormone refractory prostate cancer: initial results of CALGB 90006. J. Clin. Oncol.22, 1578 (2003)
   Google Scholar
• Yabu T, Tomimoto H, Taguchi H et al. Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate. Blood106(1), 125–134 (2005).
   PubMed Web of Science ®Google Scholar
• Figg WD, Dahut W, Duray P et al. A randomized Phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin. Cancer Res.7(7), 1888–1893 (2001).
   PubMed Web of Science ®Google Scholar
• Ning YM, Arlen P, Gulley JL et al. A Phase II trial of thalidomide, bevacizumab, and docetaxel in patients with metastatic androgen-independent prostate cancer. J. Clin. Oncol.25(Suppl. 18), 5114 (2007)
   Google Scholar
• Ben-Shoshan M, Amir S, Dang DT, Dang LH, Weisman Y, Mabjeesh NJ. 1α,25-dihydroxyvitamin D3 (calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. Mol. Cancer Ther.6(4), 1433–1439 (2007).
   PubMed Web of Science ®Google Scholar
• Beer TM, Ryan CW, Venner PM et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J. Clin. Oncol.25(6), 669–674 (2007).
   PubMed Web of Science ®Google Scholar
• Beer TM, Venner PM, Ryan CW et al. High dose calcitriol may reduce thrombosis in cancer patients. Br. J. Haematol.135(3), 392–394 (2006).
   PubMed Web of Science ®Google Scholar
• Venner PM, Ryan C, Petrylak DP et al. Reduced thromboembolic events with DN-101 (high-dose calcitriol) treatment of androgen-independent prostate cancer: hypothesis for a new class of anticoagulants. J. Clin. Oncol.24(Suppl. 18), 4505 (2006)
   Google Scholar
• Ohsawa M, Koyama T, Yamamoto K et al. 1a,25-dihydroxyvitamin D3 and its potent synthetic analogs downregulate tissue factor and upregulate thrombomodulin expression in monocytic cells, counteracting the effects of tumor necrosis factor and oxidized LDL. Circulation102(23), 2867–2872 (2000).
   PubMed Web of Science ®Google Scholar
• Wosikowski K, Lamphere L, Unteregger G et al. Preclinical antitumor activity of the oral platinum analog satraplatin. Cancer Chemother. Pharmacol.60(4), 589–600 (2007).
   PubMed Web of Science ®Google Scholar
• Sternberg CN. Satraplatin in the treatment of hormone-refractory prostate cancer. BJU Int.96(7), 990–994 (2005).
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Whelan P, Hetherington J et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs prednisone alone in patients with hormone-refractory prostate cancer. Oncology68(1), 2–9 (2005).
   PubMed Web of Science ®Google Scholar
• Latif T, Wood L, Connell C et al. Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily × 5 in hormone refractory prostate cancer. Invest. New Drugs.23(1), 79–84 (2005).
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Sartor O, Witjes O et al. A phase III, randomized, double-blind trial of satraplatin and prednisone vs. placebo and prednisone for patients with hormone refractory prostate cancer. Presented at: Prostate Cancer Symposium. Orlando, FL, USA, 22–24 February (2007)
   Google Scholar
• Sternberg CN, Petrylak D, Witjes F et al. Satraplatin demonstrates significant clinical benefits for the treatment of patients with HRPC: Results of a randomized Phase III trial. J. Clin. Oncol. (Abstract 5019).25(Suppl. 18), February (2007)
   PubMedGoogle Scholar
• Hussain M, Tangen CN, Lara PN Jr et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J. Clin. Oncol.23(34), 8724–8729 (2005).
   PubMed Web of Science ®Google Scholar
• Galsky MD, Small EJ, Oh WK et al. Multi-institutional randomized Phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J. Clin. Oncol.23(7), 1439–1446 (2005).
   PubMed Web of Science ®Google Scholar
• Smaletz O, Galsky M, Scher HI et al. Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration. Ann. Oncol.14(10), 1518–1524 (2003).
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, Weinberg VK, Beer T et al. NCI 7347: Phase I/II trial of epothilone analog BMS-247550 (ixabepilone), mitoxantrone, and prednisone in hormone refractory prostate cancer patients previously treated with chemotherapy. Presented at: Prostate Cancer Symposium. Orlando, FL, USA, 22–24 February, 2007 (Abstract 266).
   Google Scholar
• Rosenberg JE, Weinberg VK, Kelly WK et al. Randomized Phase II study of ixabepilone or mitoxantrone and prednisone in patients with taxane resistant hormone refractory prostate cancer. J. Clin. Oncol.24(Suppl. 18), 523 (2006).
   PubMedGoogle Scholar
• Guise TA, Mohammad KS. Endothelins in bone cancer metastases. Cancer Treat. Res.118, 197–212 (2004).
   PubMedGoogle Scholar
• Nelson JB, Chin JL, Love W et al. Results of a Phase 3 randomized controlled trial of the safety and efficacy of atrasentan in men with nonmetastatic hormone-refractory prostate cancer (HRPC). J. Clin. Oncol.25(Suppl. 18) (2007) (Abstract 5018).
   Google Scholar
• Nelson JB, Chin JL, Love W et al. Results of a Phase III randomized controlled trial of the safety and efficacy of atrasentan in men with nonmetastatic hormone-refractory prostate cancer (HRPC). J. Clin. Oncol. 2007 ASCO Annual Meeting Proceedings. Part I.25(Suppl. 18), 5018 (2007).
   Google Scholar
• Wilhelm S, Chien DS. BAY 43–9006: preclinical data. Curr. Pharm. Des.8(25), 2255–2257 (2002).
   PubMed Web of Science ®Google Scholar
• Dahut WL, Scripture CD, Posada M et al. Bony metastatic disease responses to sorafenib (BAY 43-9006) independent of PSA in patients with metastatic androgen independent prostate cancer. J. Clin. Oncol. ASCO Annual Meeting Proceedings Part I.24(Suppl. 18), 4506 (2006).
   Google Scholar
• Steinbild S, Mross K, Morant D et al. Phase II study of Sorafenib (BAY 43-9006) in hormone-refractory patients with prostate cancer: a study of the Central European Society for Anticancer Drug Research – EWIV (CESAR). J. Clin. Oncol.24(Suppl. 18), 3094 (2006).
   Google Scholar
• Sanda MG, Ayygari SR, Jaffee EM et al. Demonstration of a rational strategy for human prostate cancer gene therapy. J. Urol.151(3), 622–628 (1994).
   PubMed Web of Science ®Google Scholar
• Tas MP, Simons PJ, Balm FJ et al. Depressed monocyte polarization and clustering of dendritic cells in patients with head and neck cancer: in vitro restoration of this immunosuppression by thymic hormones. Cancer Immunol. Immunother.36(2), 108–114 (1993).
   PubMed Web of Science ®Google Scholar
• Carlsson B, Totterman TH, Essand M. Generation for cytotoxic T lymphocytes specific for the prostate and breast tissue antigen TARP. Prostate61(2), 161–170 (2004).
   PubMedGoogle Scholar
• Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol.24(19), 3089–3094 (2006).
   PubMed Web of Science ®Google Scholar
• Simons JW, Sacks N. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. Urol. Oncol.24(5), 419–424 (2006).
   PubMed Web of Science ®Google Scholar
• Warren TL, Weiner GJ. Uses of granulocyte-macrophage colony-stimulating factor in vaccine development. Curr. Opin. Hematol.7(3), 168–173 (2000).
   PubMed Web of Science ®Google Scholar
• Halabi S, Small E, Kantoff PW et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J. Clin. Oncol.21(7), 1232–1237 (2003).
   PubMed Web of Science ®Google Scholar
• Simons JW, Small E, Nelson W et al. Phase II trials of a GM-CSF gene-transduced prostate cancer cell line vaccine (GVAX) demonstrate anti-tumor activity. Proc. Am. Soc. Clin. Oncol.20, 1073 (2001).
   Google Scholar
• Simons J, Nelson W, Nemunaitis J et al. Phase II trials of a GM-CSF gene-transduced prostate cancer cell line vaccine (GVAX) in hormone refractory prostate cancer. Proc. Am. Soc. Clin. Oncol.21, 729 (2002).
   Google Scholar
• Small EJ, Higano C, Smith D et al. A Phase II study of an allogeneic GM-CSF gene-transduced prostate cancer cell line vaccine in patients with metastatic hormone-refractory prostate cancer. Proc. Am. Soc. Clin. Oncol.23, 396 (2004) (Abstract 4565).
   Google Scholar
• Small EJ, Tchekmedyian NS, Rini BI et al. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin. Cancer Res.13(6), 1810–1815 (2007).
   PubMed Web of Science ®Google Scholar
• Fong L, Kavanaugh B, Hou Y et al. Combination immunotherapy with GM-CSF and CTLA-4 blockade for hormone refractory prostate cancer: balancing the expansion of activated effector and regulatory T cells. J. Clin. Oncol.25(Suppl. 18), 3001 (2007).
   PubMedGoogle Scholar
• Reuben JM, Lee BN, Li C et al. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer106(11), 2437–2444 (2006).
   PubMed Web of Science ®Google Scholar
• Gerritsen W, Den Eertwegh AJ, De Gruijl TD et al. A dose-escalation trial of GM-CSF-gene transduced allogeneic prostate cancer cellular immunotherapy in combination with fully human anti-CTL4 antibody (MDX-010, ipilimumab) in patients with metastatic hormone-refractory prostate cancer (MHRPC). Presented at: Prostate Cancer Symposium. Orlando, FL, USA, 22–24 February, 2007 (Abstract 262).
   Google Scholar
• Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol.14(6), 1756–1764 (1996).
   PubMed Web of Science ®Google Scholar
• Arlen PM, Gulley JL, Parker C et al. A randomized phase II study of concurrent docetaxel plkus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin. Cancer Res.12(4), 1260–1269 (2006).
   PubMed Web of Science ®Google Scholar
• Attard G, Yap TA, Reid AH et al. Phase I study of continuous oral dosing of an irreversible CYP17 inhibitor, abiraterone in castration refractory prostate cancer patients incorporating the evaluation of androgens and steroid metabolites in plasma and tumor. J. Clin. Oncol.25(Suppl. 18), 5063 (2007).
   PubMedGoogle Scholar